BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomori O, Kolawole MO. Ebola virus disease: current vaccine solutions. Curr Opin Immunol 2021;71:27-33. [PMID: 33873076 DOI: 10.1016/j.coi.2021.03.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Fang Z, Lyu J, Li J, Li C, Zhang Y, Guo Y, Wang Y, Zhang Y, Chen K. Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects. Front Bioeng Biotechnol 2022;10:921755. [DOI: 10.3389/fbioe.2022.921755] [Reference Citation Analysis]
2 Guan R, Pang H, Liang Y, Shao Z, Gao X, Xu D, Feng X. Discovering trends and hotspots of biosafety and biosecurity research via machine learning. Brief Bioinform 2022:bbac194. [PMID: 35596953 DOI: 10.1093/bib/bbac194] [Reference Citation Analysis]
3 Alizadeh M, Amini-Khoei H, Tahmasebian S, Ghatrehsamani M, Ghatreh Samani K, Edalatpanah Y, Rostampur S, Salehi M, Ghasemi-Dehnoo M, Azadegan-Dehkordi F, Sanami S, Bagheri N. Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach. Sci Rep 2022;12:7757. [PMID: 35545650 DOI: 10.1038/s41598-022-11851-z] [Reference Citation Analysis]
4 Fulber JPC, Kamen AA. Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses 2022;14:975. [DOI: 10.3390/v14050975] [Reference Citation Analysis]
5 Hofmeyer KA, Bianchi KM, Wolfe DN. Utilization of Viral Vector Vaccines in Preparing for Future Pandemics. Vaccines 2022;10:436. [DOI: 10.3390/vaccines10030436] [Reference Citation Analysis]
6 Pérez P, Lázaro-Frías A, Zamora C, Sánchez-Cordón PJ, Astorgano D, Luczkowiak J, Delgado R, Casasnovas JM, Esteban M, García-Arriaza J. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Front Immunol 2021;12:824728. [PMID: 35154086 DOI: 10.3389/fimmu.2021.824728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Fulber JPC, Farnós O, Kiesslich S, Yang Z, Dash S, Susta L, Wootton SK, Kamen AA. Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures. Vaccines (Basel) 2021;9:1335. [PMID: 34835266 DOI: 10.3390/vaccines9111335] [Reference Citation Analysis]
8 Zhao Z, Anselmo AC, Mitragotri S. Viral vector‐based gene therapies in the clinic. Bioengineering & Transla Med 2022;7. [DOI: 10.1002/btm2.10258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tsakiri M, Naziris N, Demetzos C. Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. Int J Pharm 2021;610:121212. [PMID: 34687816 DOI: 10.1016/j.ijpharm.2021.121212] [Reference Citation Analysis]
10 Kyei-Barffour I, Addo SA, Aninagyei E, Ghartey-Kwansah G, Acheampong DO. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. Biomed Pharmacother 2021;144:112282. [PMID: 34624675 DOI: 10.1016/j.biopha.2021.112282] [Reference Citation Analysis]
11 Cheema TN, Naz S. Numerical computing with Levenberg–Marquardt backpropagation networks for nonlinear SEIR Ebola virus epidemic model. AIP Advances 2021;11:095205. [DOI: 10.1063/5.0056196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 García-Arriaza J, Esteban M, López D. Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus. Biomedicines 2021;9:1122. [PMID: 34572308 DOI: 10.3390/biomedicines9091122] [Reference Citation Analysis]
13 Bhattarai N, Pavadai E, Pokhrel R, Baral P, Hossen ML, Stahelin RV, Chapagain PP, Gerstman BS. Ebola virus protein VP40 binding to Sec24c for transport to the plasma membrane. Proteins 2021. [PMID: 34431571 DOI: 10.1002/prot.26221] [Reference Citation Analysis]
14 Bentley EM, Richardson S, Derveni M, Rijal P, Townsend AR, Heeney JL, Mattiuzzo G, Wright E. Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay. Trop Med Infect Dis 2021;6:155. [PMID: 34449756 DOI: 10.3390/tropicalmed6030155] [Reference Citation Analysis]
15 Banerjee G, Shokeen K, Chakraborty N, Agarwal S, Mitra A, Kumar S, Banerjee P. Modulation of immune response in Ebola virus disease. Curr Opin Pharmacol 2021;60:158-67. [PMID: 34425392 DOI: 10.1016/j.coph.2021.07.004] [Reference Citation Analysis]
16 Rodeghiero F, Balduini CL. A new enemy is emerging in the fight against the SARS-CoV-2 pandemic. Haematologica 2021;106:2040-1. [PMID: 34011139 DOI: 10.3324/haematol.2021.279186] [Reference Citation Analysis]
17 Sharma AR, Lee YH, Nath S, Lee SS. Recent developments and strategies of Ebola virus vaccines. Curr Opin Pharmacol 2021;60:46-53. [PMID: 34329960 DOI: 10.1016/j.coph.2021.06.008] [Reference Citation Analysis]
18 Rapaka RR, Cross AS, McArthur MA. Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines. Vaccines (Basel) 2021;9:820. [PMID: 34451945 DOI: 10.3390/vaccines9080820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol 2021;71:111-6. [PMID: 34330017 DOI: 10.1016/j.coi.2021.07.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]